Sabrina Digiovanni

Dr. Sabrina Digiovanni

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Cancer Letters
Verified
Journal Article
Open access
SVSofia La Vecchia
Sofia La Vecchia
SFSimona Fontana
Simona Fontana
ISIris Chiara Salaroglio
Iris Chiara Salaroglio
DADario Pasquale Anobile
Dario Pasquale Anobile
SDSabrina Digiovanni
Sabrina Digiovanni
Chiara RigantiChiara Riganti
Chiara Riganti
Immune checkpoints inhibitors (ICIs) as anti-PD-1/anti-PD-L1 have been approved as first-line treatment in patients with non-small cell lung cancer (NSCLC), but only 25 % of patients achieve durable response. We previously unveiled that estrogen receptor α transcriptionally up-regulates PD-L1 and aromatase inhibitors such as letrozole increase the efficacy of pembrolizumab. Here we investigated if letrozole may have additional immune-sensitizing mechanisms. We found that higher the level of PD-L1 in NSCLC, higher the activation of SREBP1c that transcriptionally increases fatty acid synthase and stearoyl-CoA desaturase enzymes, increasing the amount of polyunsaturated fatty acids (PUFAs). Letrozole further up-regulated SREBP1c-mediated transcription of lipogenic genes, and increased the amount of PUFAs, thereby leading to greater membrane fluidity and reduced binding between PD-L1 and PD-1. The same effects were observed upon supplementation with ω3-PUFA docosahexaenoic acid (DHA) that enhanced the efficacy of pembrolizumab in humanized NSCLC immune-xenografts. We suggest that PUFA enrichment in membrane phospholipids improves the efficacy of ICIs. We propose to repurpose letrozole or DHA as new immune-sensitizing agents in NSCLC.

2 July 2026 in International Endodontic Journal
Verified
Journal Article
Open access
LBLoredana Bergandi
Loredana Bergandi
Alovisi MarioAlovisi Mario
Alovisi Mario
ETElena Tachis
Elena Tachis
Nicola ScottiNicola Scotti
Nicola Scotti
ABAndrea Baldi
Andrea Baldi
DPDamiano Pasqualini
Damiano Pasqualini
Aim: A growing body of research supports an association between periapical inflammation and an increased risk of various systemic effects. However, there is currently no scientific evidence demonstrating a causal relationship between this inflammation and changes in epithelial or endothelial permeability in patients with apical periodontitis (AP). This study aimed to evaluate the potential association between AP, circulating inflammatory cytokines known to affect cellular permeability, and serum proteins associated with an impaired cellular barrier permeability. Additionally, we investigated the effect of endodontic treatment on in vitro endothelial barrier integrity. Methodology: A total of 27 patients with AP and 27 healthy control subjects were enrolled. AP patients underwent root canal treatment and were followed up at 6 and 12 months post‐treatment. Serum levels of human ZO‐1, Claudin‐5, and VE‐cadherin were measured using enzyme‐linked immunosorbent assays (ELISA). An in vitro model of the microvascular endothelial blood–brain barrier (hCMEC/D3 cells) was used to assess the biological activity of patient sera on barrier function and cellular permeability. Results: At baseline, patients with AP showed significantly higher serum levels of ZO‐1 and Claudin‐5 compared with controls ( p < 0.001), whereas VE‐cadherin levels did not differ significantly between groups. Serum ZO‐1 and Claudin‐5 levels progressively decreased at 6 and 12 months following root canal treatment. In adjusted analyses, the baseline between‐group differences for ZO‐1 and Claudin‐5 remained significant after adjustment for BMI and smoking status. ZO‐1 and Claudin‐5 levels showed moderate correlations with IL‐1β and IL‐6 in the AP group at baseline. In vitro, exposure to baseline AP sera increased endothelial permeability, indicating barrier disruption, while sera collected after treatment did not impair barrier integrity. Moreover, cellular ZO‐1 expression remained stable in cells treated with control sera but was markedly reduced after exposure to sera from untreated AP patients (t0), whereas post‐treatment sera (t6 and t12) restored ZO‐1 expression to control levels. Conclusions: Systemic inflammation in patients with apical periodontitis to deranged endothelial barrier function. Successful endodontic treatment was associated with reduced levels of inflammatory cytokines and the restoration of serum and cellular proteins essential for barrier integrity.

15 September 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
SDSabrina Digiovanni
Sabrina Digiovanni
CGClaudia Giannotta
Claudia Giannotta
LALuca Alessandri
Luca Alessandri
SFSimona Fontana
Simona Fontana
AMAngelo Meoli
Angelo Meoli
Chiara RigantiChiara Riganti
Chiara Riganti
Non-small cell lung cancer (NSCLC) shows partial chemoimmunoresistance, driven by the upregulation of the drug efflux transporters ABCB1 and ABCC1 and the downregulation of the immunosensitizer protein ABCA1. To elucidate the molecular mechanisms underlying this chemoimmunoresistant phenotype, by performing a CRISPR-KO kinome screening, we identified interleukin-1 receptor-associated kinase 1 (IRAK1) as a key determinant of chemoimmunosensitive and chemoimmunoresistant phenotypes, defined as ABCB1/ABCC1lowABCA1high and ABCB1/ABCC1highABCA1low, respectively. IRAK1 expression was significantly associated with poor prognosis in the TCGA-LUAD cohort and in early-stage NSCLC patients. The IRAK1/ABCB1/ABCC1highABCA1low signature was predictive of poor response to chemotherapy and immunotherapy in advanced-stage patients. Mechanistically, IRAK1 silencing resensitized NSCLC cells to cisplatin by decreasing IL-1R/NFκB and IL-1R/AP-1 signaling, which in turn downregulated the drug efflux transporters ABCB1 and ABCC1. Concurrently, IRAK1 silencing activated the LXRα/ABCA1 axis, which enhanced Vγ9Vδ2 Tcell-mediated cytotoxicity and facilitated the recruitment of memory and effector CD4+ and CD8+ T cells in both ex vivo autologous cocultures and immunoxenografts, increasing the immuno-killing ability of tumor cells. Newly developed synthetic inhibitors of IRAK1 efficiently promoted chemo- and immunosensitization in immunoxenografts, resulting in good pharmacokinetic and safety profiles. These findings identify IRAK1 as a novel, druggable target that controls both chemoresistance and immune evasion in NSCLC. We suggest the pharmacological inhibition of IRAK1 as a future promising strategy to overcome resistance to chemotherapy and improve patient outcomes.